Company Overview and News

127
Shell Seen Rediscovering Its Swagger in Texas Shale Oil Country

39m rigzone
(Bloomberg) -- Shale oil hasn’t always been Royal Dutch Shell Plc’s best friend, but they’re working on the relationship.
APC BGX RDS.B RDS.A BLT BHPBF RDSB BGLF BX RDSA BGB EOG BHP RYDBF BBL BHP RYDAF BHPLF AEUA

21
Dutch gov't under fire over tax deal with Shell

2h nltimes.nl
The Tweede Kamer, the lower house of Dutch parliament, wants the government to explain a controversial deal that Shell made with the Dutch tax authorities in 2005. As a result of this deal, Shell's British shareholders are exempt from dividend tax in the Netherlands, through which the Dutch treasury lost out on over 7 billion euros, newspaper Trouw reported on Saturday.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

28
An Oil Giant Is Taking Big Steps. Saudi Arabia Can’t Afford for It to Slip. - The New York Times

5h nytimes
As the kingdom prepares for its next evolution, Saudi Aramco is central. But a planned public listing leaves the company, and the country, at risk.
RDS.B RDS.A XOM RYDBF DOW RDSB NYTAB RDSA RYDAF

50
RPT-FOCUS-Pipe dream? Chevron, Woodside vie to shape Australia's LNG sector

18h reuters
MELBOURNE, June 15 (Reuters) - After spending a decade and billions of dollars developing Australia’s vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

23
CORRECTED-Chevron moves Brazil chief to lead Venezuela ops after arrests -sources

22h reuters
(Corrects fourth paragraph to show La Rosa previously served as commercial manager in Venezuela, not country manager)
SLB RDS.B RDS.A CVX RYDBF RDSB SCL RDSA SLB RYDAF

21
Dutch MP calls for Shell dividend tax probe

2018-06-16 malaymail
THE HAGUE, June 16 — A Dutch MP called today for a parliamentary enquiry into how oil giant Royal Dutch Shell has been paying billions in share dividends through the British Channel islands without tax.
RDS.B RDS.A RYDBF RDSB RDSA RYDAF

528
Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE

63
Minister: Uruguay to Adopt Permanent Offer Process for Offshore Oil Blocks

2018-06-15 rigzone
BARILOCHE, Argentina, June 15 (Reuters) - Uruguay will move toward a permanent offer process for offshore oil blocks as other Latin American countries have done, after an April auction failed to attract bids, Industry, Energy and Mining Minister Carolina Cosse said in an interview this week.
RDS.B RDS.A XOM BP RDSB RDSA GLPEF BP.A BP.B BP RYDBF TLW BPAQF RYDAF GLPEY

53
Market report: Indivior loses a quarter of its value as copycat drug is approved

2018-06-15 telegraph.co.uk
Pharmaceutical company Indivior shed a quarter of its value on Friday after the US Food and Drug Administration approved copycat versions of its opioid dependence treatment, a blow that analysts warned could halve its profitability in 2018.
RDS.B DB RDS.A BLT BHPBF RDSB RDSA BHP RYDBF BBL TLW BHP RYDAF BHPLF

50
Pipe Dream? Chevron, Woodside Vie to Shape Australia's LNG Sector

2018-06-15 rigzone
MELBOURNE, June 15 (Reuters) - After spending a decade and billions of dollars developing Australia's vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

30
Royal Dutch Shell: Take Advantage Of Growing LNG Demand

2018-06-15 seekingalpha
Royal Dutch Shell has positioned itself incredibly well during the oil crash. The company took advantage of lows to acquire the massive BG Group.
COP BRGXF BG RDS.B BRGYY RDS.A XOM RYDBF RDSB RDSA RYDAF

50
Pipe dream? Chevron, Woodside vie to shape Australia's LNG sector

2018-06-15 channelnewsasia
MELBOURNE: After spending a decade and billions of dollars developing Australia's vast gas reserves, U.S. energy giant Chevron Corp and local firm Woodside Petroleum are at odds over the pace and timing of the next leg of expansion.
WOPEF RDS.B RDS.A BLT BHPBF RDSB RDSA WPL WOPEY BHP CVX RYDBF BBL BHP RYDAF BHPLF

22
Chevron Starts Second Production Unit at Wheatstone LNG in Australia

2018-06-15 rigzone
MELBOURNE, June 15 (Reuters) - Chevron Corp has started producing liquefied natural gas (LNG) at the second unit of its $34 billion Wheatstone development, marking the completion of its two megaprojects in Australia after cost-blowouts and delays.
WOPEF RDS.B RDS.A CVX KYSEY RYDBF RDSB RDSA RYDAF WPL WOPEY

47
5 Passive ETFs Soaring in Popularity on Millennials' Choice

2018-06-14 zacks
Millennial’s are giving more preference to ETFs as compared to stocks, in a clear indication that the former is gradually gaining the upper hand in terms of investment options. In a survey conducted by Charles Schwab, 96% said that ETFs are an essential part of their investment outlook. Per a survey by Schwab, among 1500 respondents, 32% said that they have replaced all their stocks with ETFs, while 58% has replaced a portion.
SCHW.PRBCL RDS.B RDS.A 0700 RYDBF BC94 SMSN RDSB RDSA RYDAF YY SMSD

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

10h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...